We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Clinical Chemistry Analyzer Processes 300 Tests per Hour

By Labmedica staff writers
Posted on 04 Aug 2008
A clinical chemistry analyzer has been launched for low- to medium-volume laboratories with throughput needs of up to 300 tests per hour.

Compact and reliable, the cobas c 311 analyzer is suitable for satellite, STAT, and smaller hospital laboratories. More...
It offers a comprehensive clinical chemistry menu of more than 100 assays. Up to 45 assays can be performed simultaneously. High onboard reagent stabilities and lot-to-lot calibration optimize reagent usage makes the analyzer cost-effective and convenient to use.

All reagents in the ergonomic cobas c packs are liquid and ready-to-use, and all components of a parameter are integrated into a single cassette. The integration of cobas e-services for electronic updates and downloads makes handling of application, calibrator, and control information seamless and precise. Special features of the 311 analyzer include intelligent clot detection, carryover-free ultrasonic mixing, and test-specific serum indices.

Introduced by Roche (Basel, Switzerland), the cobas c 311 analyzer represents the latest collaboration between the company and its strategic partner, Hitachi High Technologies (Tokyo, Japan). The analyzer was launched prior to the American Association of Clinical Chemistry (AACC) Congress, which was held on July 29-31, 3008, in Washington DC (USA). Dirk Ehlers, head of Roche professional diagnostics said, "The system will enable us to offer smaller laboratories many of the efficiencies and conveniences currently provided by the cobas 6000 analyzer series.”

The cobas c 311 analyzer complements the cobas 411 immunoanalyzer, which was released in December 2006. The two systems compose the cobas 4000 analyzer series, an efficient serum work-area solution designed to process more than 95% of the combined testing needs of low- to mid-volume laboratories.

Roche, a biotech company, is an innovator of products and services for the early detection, prevention, diagnosis, and treatment of diseases. Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders, and diseases of the central nervous system.


Related Links:
Roche
Hitachi High Technologies

Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.